Biomea Fusion, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BMEA | A89.F | MTVA | ENTX | IMM.L | GUTS | |
|---|---|---|---|---|---|---|
| Market cap | 44.24M | 63.00M | 8.83M | 540.90M | 21.88M | 12.90M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.7 | — | — | -5.7 | 0.0 | -0.3 |
| Price/book | 3.7 | -12.5 | 1.3 | 21.2 | 11.7 | -7.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −52.92% | −67.75% | −85.67% | 0.00% | −69.00% | −93.38% |
| Today | −1.91% | −0.62% | +6.35% | +1.97% | +7.50% | +8.27% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All BMEA news ›Fragment 176–191, Modified GRF 1–29, and Ipamorelin Blend: A Multi-Pathway Research Strategy
Published 2:23 pm Tuesday, October 20, 2026 by Fiber Traffic Digital Solutions One of the primary research interests surrounding this peptide blend involves endogenous growth hormone regulation. Modified GRF 1–29 and Ipamorelin are…
The Evolving Research Landscape of the Frag 176–191, Mod GRF 1–29, and Ipamorelin Blend
Published 4:22 pm Friday, October 16, 2026 by Fiber Traffic Digital Solutions Frag 176–191: A Specialized Fragment with Distinct Metabolic Research Properties Frag 176–191 represents the C-terminal fragment of growth hormone encompassing…
Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript
Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss October 13, 2026 4:30 PM EDT Ramses Erdtmann - Co-Founder, President, COO & DirectorThorsten Kirschberg -…
Biomea reports early weight-loss signal for oral GLP-1 drug, seeks development partner
AllSci is an AI-grounded scientific knowledge platform. It aggregates the global scientific literature, patents, grants and trials, atomizes them into hypotheses, questions, results and claims, links everything to canonical entity…
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
Investing News Network Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist - Mean weigh
Biomea Fusion releases Phase I results for BMF-650 oral GLP-1 candidate
Traders Union Biomea Fusion releases Phase I results for BMF-650 oral GLP-1 candidate Biomea Fusion announced the results from its Phase I clinical trial for BMF-650, an investigational next-generation oral small-molecule GLP-1
Biomea Fusion (NASDAQ:BMEA) Upgraded at Wall Street Zen
Posted by Mitch Edgeman on Oct 8th, 2026 Wall Street Zen upgraded shares of Biomea Fusion (NASDAQ:BMEA – Free Report) from a sell rating to a hold rating in a report issued on Monday morning,Wall Street Zen reports. Check Out Our Latest…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com2
- stocktitan.net2
- globenewswire.com1
- themarketsdaily.com1
- tradersunion.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.